Gross metropolitan product

Games Global Announces Launch of IPO

Retrieved on: 
목요일, 5월 2, 2024
Entertainment, Technology, General Entertainment, Other Technology, Electronic Games, Casino, Gaming, Sale, Prospectus, Person, Investment, EEA, Macquarie Group, Jefferies, Barclays, Finance, Exchange, Madison Avenue, Gross metropolitan product, IPO, Jefferies Group, European Economic Area, GGL, Order, Financial services, Attention, Security (finance)

Games Global Limited (“Games Global”), a leading developer, distributor and marketer of innovative online, casino-style gaming (“iGaming”) content and integrated business-to-business solutions to iGaming operators, announced today that it has launched the roadshow for its initial public offering (“IPO”) of 14,500,000 ordinary shares.

Key Points: 
  • Games Global Limited (“Games Global”), a leading developer, distributor and marketer of innovative online, casino-style gaming (“iGaming”) content and integrated business-to-business solutions to iGaming operators, announced today that it has launched the roadshow for its initial public offering (“IPO”) of 14,500,000 ordinary shares.
  • The offering consists of 6,000,000 ordinary shares offered by Games Global and 8,500,000 ordinary shares to be sold by Games Global’s existing shareholder (the “Selling Shareholder”).
  • Games Global will not receive any proceeds from the sale of the shares by the Selling Shareholder.
  • Games Global has applied to list its ordinary shares on the New York Stock Exchange under the symbol "GGL".

Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering

Retrieved on: 
월요일, 4월 22, 2024
Gross metropolitan product, Civil service commission, European Commission, Intellectual property, Gastroenterology, Quality of life, European Economic Area, Patient, Dermatology, Safety, Pharmaceutical industry

Pyzchiva® is a key biosimilar value driver for the company over the mid-term and this approval is a major step in advancing Sandoz growth strategy.

Key Points: 
  • Pyzchiva® is a key biosimilar value driver for the company over the mid-term and this approval is a major step in advancing Sandoz growth strategy.
  • This approval is a crucial step towards offering European patients an additional safe and effective treatment option and further demonstrates our commitment to pioneer access to potentially life-changing medicines."
  • Sandoz entered into a development and commercialization agreement for biosimilar ustekinumab with Samsung Bioepis in September 2023.
  • Under the terms of the agreement, Sandoz has the right to commercialize Pyzchiva® in the US, Canada, the European Economic Area (EEA), Switzerland, and the UK.

Games Global Announces Filing of Registration Statement for Proposed Initial Public Offering

Retrieved on: 
수요일, 4월 17, 2024
Entertainment, Technology, General Entertainment, Other Technology, Electronic Games, Casino, Gaming, Sale, Prospectus, Investment, Broadridge Financial Solutions, EEA, Macquarie Group, Jefferies, Barclays, Finance, Madison Avenue, Gross metropolitan product, Form, Jefferies Group, European Economic Area, GGL, Order, Financial services, Attention, Telephone, Person, Security (finance)

The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined.

Key Points: 
  • The timing of the offering, number of shares to be offered and the price range for the proposed offering have not yet been determined.
  • Games Global has applied to list its ordinary shares on the New York Stock Exchange under the symbol "GGL".
  • J.P. Morgan, Jefferies and Macquarie Capital are acting as joint book-running managers for the proposed offering.
  • These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.

United Kingdom International Remittance Business Report 2024: Payment Service Providers are Launching New Products to Simplify Remittances for their Users - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
금요일, 4월 12, 2024
Technology, Payments, Mastercard, Revolut, Indian stock exchange, Gross metropolitan product, M-Pesa, European Economic Area, Government, Business, Growth, Financial services

The international inbound remittance market in United Kingdom has increased at 7.8% during 2023 to reach US$ 4.45 billion in 2024.

Key Points: 
  • The international inbound remittance market in United Kingdom has increased at 7.8% during 2023 to reach US$ 4.45 billion in 2024.
  • The remittance industry is expected to record steady growth over the medium term in the United Kingdom.
  • Amid the fast-growing competitive landscape in the United Kingdom and the global remittance industry, payment service providers are launching new products to simplify remittances for their users globally.
  • Actionable Insights for Businesses and Investors: The report provides data centric analysis for businesses and investors operating in the United Kingdom remittance market.

Cv International Receives CE Certification for Six Nitrogen Servicing Products

Retrieved on: 
목요일, 4월 11, 2024
Safety, Certification, Health, CVI, Collection, Growth hacking, Gross metropolitan product, Wind, European Economic Area, Aviation, CE, Medical device

BEND, Ore., April 11, 2024 /PRNewswire/ -- Cv International (Cvi), a leading provider of nitrogen generation and servicing solutions, is proud to announce that it has achieved CE certification for six of its nitrogen servicing products .

Key Points: 
  • BEND, Ore., April 11, 2024 /PRNewswire/ -- Cv International (Cvi), a leading provider of nitrogen generation and servicing solutions, is proud to announce that it has achieved CE certification for six of its nitrogen servicing products .
  • The CE mark confirms that Cvi's products meet the high safety, health, and environmental protection requirements of the European Economic Area (EEA).
  • "Receiving the CE certification for our nitrogen servicing products is a significant milestone for Cv International," said Dan Warden, CEO of Cv International.
  • With this latest certification, Cvi is poised to extend its presence in the European market, introducing its innovative nitrogen servicing solutions, including Cvi's WindKit , wind turbine nitrogen servicing unit, to a wider audience.

Shareholders of Meyer Burger approve rights issue of around CHF 200 million and support the expansion of the production and distribution structures in the United States

Retrieved on: 
수요일, 4월 10, 2024
European Economic Area, Gross metropolitan product, Finance, Financial services, Prospectus, Publication, Person, FSMA

Meyer Burger Technology AG assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Key Points: 
  • Meyer Burger Technology AG assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
  • This document is not an offer to sell or a solicitation of offers to purchase or subscribe for any securities.
  • A decision to invest in securities of Meyer Burger Technology AG should be based exclusively on the prospectus to be published by Meyer Burger Technology AG for such purpose.
  • Any person who is not a relevant person should not act or rely on this document or any of its contents.

Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

Retrieved on: 
수요일, 3월 20, 2024
Joint venture, Patient, Sale, Business analyst, CCHN, IP, Marketing, Research, Mallinckrodt, Absorption, European Economic Area, Gross metropolitan product, Webcast, Asset, Alvogen, Denosumab, Neovascularization, Biosimilar, Macular degeneration, Safety, Food, U.S. FDA, Teva Pharmaceuticals, Revenue, Q3, CES, AMD, FDA, ISK, Administration, Adalimumab, Research and development, Pharmaceutical industry

Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).

Key Points: 
  • Management will conduct a business update conference all and live webcast on March 21, 2024 at 8:00 am ET (12:00 pm GMT).
  • Alvotech announced positive top-line results from a pharmacokinetic (PK) study for AVT05, a biosimilar candidate to Simponi® and Simponi Aria® (golimumab).
  • Alvotech announced positive top-line results from a PK study for AVT03, a biosimilar candidate to Prolia® and Xgeva®, which both contain denosumab.
  • Alvotech will conduct a business update conference call and live webcast on Thursday, March 21, 2024, at 8:00 am ET (12:00 pm GMT).

Altria Enters $2.4 Billion Accelerated Share Repurchase Transactions in Connection with Closing of Offering of Anheuser-Busch InBev Stock

Retrieved on: 
화요일, 3월 19, 2024
Tobacco, Retail, Professional Services, Finance, European Economic Area, Gross metropolitan product, Goldman Sachs, ASR, ABI, Sale, ANB, ADS, AB InBev, Risk, Euronext, Annual report, Share repurchase, Security (finance)

Altria Group, Inc. (Altria) (NYSE: MO) today announces that we entered accelerated share repurchase (ASR) transactions under separate agreements with Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on March 15, 2024, to repurchase $2.4 billion of our common stock.

Key Points: 
  • Altria Group, Inc. (Altria) (NYSE: MO) today announces that we entered accelerated share repurchase (ASR) transactions under separate agreements with Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC on March 15, 2024, to repurchase $2.4 billion of our common stock.
  • We expect the remainder of the shares to be delivered no later than the end of the second quarter of 2024.
  • The ASR transactions are part of our expanded $3.4 billion share repurchase program, which we expect to complete by December 31, 2024.
  • In addition, ABI repurchased $200 million of ordinary shares directly from us, concurrently with the completion of the offering.

Altria to Significantly Enhance Cash Returns to Shareholders Through Expanded Share Repurchase Program in Connection with Pricing of Offering of Anheuser-Busch InBev Stock; Raises 2024 Full-Year Earnings Guidance

Retrieved on: 
목요일, 3월 14, 2024
Tobacco, Retail, Wine & Spirits, Health, Uncertainty, Climate change, European Economic Area, Growth, Gross metropolitan product, Exercise, MSA, EPS, Risk, Accounting, Law enforcement, Food and Drug Administration, Climate, ASR, History, Sale, Acquisition, ANB, Private sector, ADS, AB InBev, Euronext, Artificial intelligence, Investment, Annual report, Heated tobacco product, NPM, GAAP, Vision, Income tax, Information, Pandemic, Privacy, Food, Share repurchase, Security (finance)

In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.

Key Points: 
  • In connection with the pricing of the offering, we announce a $2.4 billion increase to our existing $1 billion share repurchase program.
  • Our Board of Directors (Board) has authorized the expanded program, which we expect to complete by December 31, 2024.
  • Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board.
  • As part of the expanded share repurchase program, we expect to enter into an estimated $2.4 billion accelerated share repurchase (ASR) program.

Altria Announces Intent to Sell a Portion of its Investment in Anheuser-Busch InBev

Retrieved on: 
수요일, 3월 13, 2024
Tobacco, Retail, Wine & Spirits, European Economic Area, Gross metropolitan product, Telephone, EDGAR, ABI, Sale, ANB, ADS, Risk, Euronext, Prospectus, Morgan Stanley, Broadridge Financial Solutions, Annual report, Varick Street, Beer, 2nd Floor, Security (finance)

In addition, ABI has agreed to repurchase $200 million of ordinary shares directly from Altria, concurrently with, and conditional on, completion of the offering.

Key Points: 
  • In addition, ABI has agreed to repurchase $200 million of ordinary shares directly from Altria, concurrently with, and conditional on, completion of the offering.
  • Altria, as the selling shareholder, is offering 35 million of ABI’s ordinary shares.
  • In addition, we have agreed to a 180-day lockup with the lead underwriter for our remaining ABI shares.
  • “Over the decades of our ownership, the beer investment has provided significant income and cash returns and supported our strong balance sheet.